Literature DB >> 26227369

Successful methodology for large-scale surveillance of severe events following influenza vaccination in Canada, 2011 and 2012.

J A Bettinger1, I Rouleau, M C Gariepy, W R Bowie, L Valiquette, O G Vanderkooi, J D Kellner, B L Coleman, S A McNeil, A McCarthy, G De Serres.   

Abstract

In 2011 and 2012, a nationwide Canadian vaccine safety surveillance network rapidly collected safety data from healthcare workers (HCW) during the first weeks of the annual influenza vaccination campaign. This network provided the first available post-marketing safety data on seasonal influenza vaccines with information on background rates as a comparator. In 2012, these data were used to investigate a possible safety concern regarding a particular vaccine. An online questionnaire was provided to participating HCW two weeks before the annual influenza vaccination campaign for controls, and eight days after influenza vaccination for vaccinees. Control and vaccinees were requested to report health events occurring in the seven days prior to receiving the questionnaire. Control data were used to calculate background rates. HCW reporting a severe event were followed-up by telephone within 48 hours of the online report to validate the report and check on their health status. More than 22,000 vaccinated HCW were enrolled and surveyed over two seasons and > 90% reported no severe event following vaccination. Validated severe event rates were similar in vaccinated HCW and unvaccinated HCW (2.2% vs 2.3%; p < 0.70). The questionnaire was accurately completed for most reported symptoms, matched the validated report and was able to detect events of interest. Prior to the safety concern, the implicated vaccine was in use at one centre. Reassuring safety data were provided to public health authorities 48 hours after the vaccine was temporarily suspended. Data from this and similar networks can be used for rapid evaluation of vaccine safety and for safety assessment as required by the European Medicines Agency in 2015.

Mesh:

Substances:

Year:  2015        PMID: 26227369     DOI: 10.2807/1560-7917.es2015.20.29.21189

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  6 in total

1.  An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination.

Authors:  Kumanan Wilson; Katherine M Atkinson; Jacqueline Westeinde; Cameron Bell; Kim Marty; Dean Fergusson; Shelley L Deeks; Natasha Crowcroft; Julie A Bettinger
Journal:  Hum Vaccin Immunother       Date:  2016-02-23       Impact factor: 3.452

Review 2.  Participant-centred active surveillance of adverse events following immunisation: a narrative review.

Authors:  Patrick Cashman; Kristine Macartney; Gulam Khandaker; Catherine King; Michael Gold; David N Durrheim
Journal:  Int Health       Date:  2017-05-01       Impact factor: 2.473

3.  Comparison of response rates on invitation mode of a web-based survey on influenza vaccine adverse events among healthcare workers: a pilot study.

Authors:  Xiaochen Tai; Alanna M Smith; Allison J McGeer; Eve Dubé; Dorothy Linn Holness; Kevin Katz; Linda McGillis Hall; Shelly A McNeil; Jeff Powis; Brenda L Coleman
Journal:  BMC Med Res Methodol       Date:  2018-06-20       Impact factor: 4.615

4.  2017/18 and 2018/19 seasonal influenza vaccine safety surveillance, Canadian National Vaccine Safety (CANVAS) Network.

Authors:  Julie A Bettinger; Gaston De Serres; Louis Valiquette; Otto G Vanderkooi; James D Kellner; Brenda L Coleman; Karina A Top; Jennifer E Isenor; Anne E McCarthy
Journal:  Euro Surveill       Date:  2020-06

Review 5.  Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives.

Authors:  Gaël Dos Santos
Journal:  Hum Vaccin Immunother       Date:  2019-05-22       Impact factor: 3.452

6.  The Canadian National Vaccine Safety Network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada.

Authors:  Julie A Bettinger; Manish Sadarangani; Gaston De Serres; Louis Valiquette; Otto G Vanderkooi; James D Kellner; Matthew P Muller; Karina A Top; Jennifer E Isenor; Allison McGeer; Kimberly Marty
Journal:  BMJ Open       Date:  2022-01-20       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.